Paul A Kurz1, Lena V Chheda, Daryl E Kurz. 1. Ohio State University, Havener Eye Institute, 915 Olentangy River Road, Columbus, OH 43212, USA. paul.kurz@osumc.edu
Abstract
PURPOSE: To report the effects of twice-daily difluprednate in a child with pars planitis (PP). DESIGN/ METHODS: Case report. RESULTS: PP was controlled with topical difluprednate for 1 year. Then an atypical pattern of steroid response--delayed, relatively sudden onset of recalcitrant ocular hypertension (OHT)--and posterior subcapsular cataract (PSC) formation necessitated alternative treatment. CONCLUSION: Although not a standard treatment, in select cases of PP topical difluprednate therapy could be a useful short-term treatment option while alternative treatments are considered or immunosuppressive agents build to therapeutic levels. Ophthalmologists must be aware of the potential for delayed onset of serious complications when using difluprednate.
PURPOSE: To report the effects of twice-daily difluprednate in a child with pars planitis (PP). DESIGN/ METHODS: Case report. RESULTS: PP was controlled with topical difluprednate for 1 year. Then an atypical pattern of steroid response--delayed, relatively sudden onset of recalcitrant ocular hypertension (OHT)--and posterior subcapsular cataract (PSC) formation necessitated alternative treatment. CONCLUSION: Although not a standard treatment, in select cases of PP topical difluprednate therapy could be a useful short-term treatment option while alternative treatments are considered or immunosuppressive agents build to therapeutic levels. Ophthalmologists must be aware of the potential for delayed onset of serious complications when using difluprednate.
Authors: John D Sheppard; Melissa M Toyos; John H Kempen; Paramjit Kaur; C Stephen Foster Journal: Invest Ophthalmol Vis Sci Date: 2014-05-06 Impact factor: 4.799
Authors: Ricardo J Cumba; Kundandeep S Nagi; Nicholas P Bell; Lauren S Blieden; Alice Z Chuang; Kimberly A Mankiewicz; Robert M Feldman Journal: ISRN Ophthalmol Date: 2013-06-26